skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Stereotactic Ablative Radiation Therapy as First Local Therapy for Lung Oligometastases From Colorectal Cancer: A Single-Institution Cohort Study

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [3];  [1];  [2];  [4];  [1];  [4];  [1]
  1. Department of Oncology, Radiation Oncology, University of Torino, Torino (Italy)
  2. Cancer Epidemiology and CPO Piemonte, Città della Salute e della Scienza, Torino (Italy)
  3. Radiation Oncology, Città della Salute e della Scienza, Torino (Italy)
  4. Medical Oncology, Colorectal Cancer Unit, Città della Salute e della Scienza, Torino (Italy)

Purpose: To estimate stereotactic ablative radiation therapy (SABR) efficacy and its potential role as an alternative to surgery for the treatment of lung metastases from colorectal cancer. Methods and Materials: Forty consecutive patients who received SABR as first local therapy at the time of lung progression were included, from 2004 to 2014. The primary study endpoint was overall survival. Secondary endpoints were progression-free survival and safety. Results: A single nodule was treated in 26 patients (65%), 2 nodules in 10 patients (25%), 3 in 3 patients (7.5%), and 4 in 1 patient (2.5%), for a total of 59 lesions. The median delivered biological effective dose was 96 Gy, in 1 to 8 daily fractions. Median follow-up time was 20 months (range, 3-72 months). Overall survival rates at 1, 2, and 5 years were, respectively, 84%, 73%, and 39%, with 14 patients (35%) dead. Median overall survival was 46 months. Progression occurred in 25 patients (62.5%), at a median interval of 8 months; failure at SABR site was observed in 3 patients (7.5%). Progression-free survival rates were 49% and 27% at 1 and 2 years, respectively. Discussion: The results of this retrospective exploratory analysis suggest safety and efficacy of SABR in patients affected with colorectal cancer lung oligometastases and urge inclusion of SABR in prospective clinical trials.

OSTI ID:
22458621
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 91, Issue 3; Other Information: Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
Journal Article · Sat Aug 01 00:00:00 EDT 2015 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22458621

Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter
Journal Article · Thu Jun 01 00:00:00 EDT 2017 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22458621

Stereotactic Body Radiation Therapy for Oligometastases to the Lung: A Phase 2 Study
Journal Article · Sun Feb 01 00:00:00 EST 2015 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22458621